DDInter1042 DDInter640
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Encorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifaximin
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Grepafloxacin
Encorafenib {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Encorafenib may lead to a major life threatening interaction when taken with Grepafloxacin
Encorafenib may lead to a major life threatening interaction when taken with Lorlatinib